{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Diaz-Anton B"],"funding":["European Social Fund","Instituto de Salud Carlos III","Comunidad de Madrid"],"pagination":["1127-1137"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8934964"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["9(2)"],"pubmed_abstract":["Aims
To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation.Methods and results
Seventy-two women with breast cancer (52 ± 9.8 years) treated with anthracyclines (26 also with trastuzumab), were evaluated for 14 months (6 echocardiograms/12 laboratory tests). We analysed: high-sensitivity cardiac troponin T, NT-proBNP, global longitudinal strain (GLS), left ventricle end-systolic volume (LVESV), left ventricle end-diastolic volume (LVEDV), and left ventricular ejection fraction (LVEF). Cardiotoxicity was defined as a reduction in LVEF>10% compared with baseline with LVEF<53%. High-sensitivity troponin T levels rose gradually reaching a maximum p"],"journal":["ESC heart failure"],"pubmed_title":["Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters."],"pmcid":["PMC8934964"],"funding_grant_id":["B2017/BMD‐3676","PI20/01238","PI15/02019","AORTASANA‐CM"],"pubmed_authors":["Ramirez Merino N","Castellano JM","Moreno-Arciniegas A","Lopez-Melgar B","Madurga R","Parra Jimenez FJ","Ciruelos E","Martin-Asenjo R","Fernandez-Friera L","Solis J","Zorita B","Diaz-Anton B","Wasniewski S","Amado Escanuela MG","Barrio P"],"additional_accession":[]},"is_claimable":false,"name":"Early detection of anthracycline- and trastuzumab-induced cardiotoxicity: value and optimal timing of serum biomarkers and echocardiographic parameters.","description":"Aims
To evaluate echocardiographic and biomarker changes during chemotherapy, assess their ability to early detect and predict cardiotoxicity and to define the best time for their evaluation.Methods and results
Seventy-two women with breast cancer (52 ± 9.8 years) treated with anthracyclines (26 also with trastuzumab), were evaluated for 14 months (6 echocardiograms/12 laboratory tests). We analysed: high-sensitivity cardiac troponin T, NT-proBNP, global longitudinal strain (GLS), left ventricle end-systolic volume (LVESV), left ventricle end-diastolic volume (LVEDV), and left ventricular ejection fraction (LVEF). Cardiotoxicity was defined as a reduction in LVEF>10% compared with baseline with LVEF<53%. High-sensitivity troponin T levels rose gradually reaching a maximum p","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Apr","modification":"2025-04-26T04:39:57.111Z","creation":"2025-04-06T11:12:51.441Z"},"accession":"S-EPMC8934964","cross_references":{"pubmed":["35106939"],"doi":["10.1002/ehf2.13782"]}}